Monument Therapeutics Secures £850k to Advance Breakthrough Schizophrenia Treatment
Manchester, UK, 25 February 2025 Monument Therapeutics, an innovative neuroscience company applying digital biomarkers to psychiatric drug development, has secured £850k in further funding led by ACF Investors, with participation from Wren Capital, o2h Ventures, and angel investors. The investment will be used to fund its schizophrenia programme and drive the next stage of growth […]
Monument Therapeutics Announces Grant of Chinese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program
Manchester, UK, 21 January 2025 Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the China National Intellectual Property Administration (“CNIPA”) has granted Chinese patent ZL202080036867.6, in support of its MT1988 program for cognitive impairment associated with schizophrenia (CIAS). The patent, […]
Monument Therapeutics Announces Grant of Japanese Patent in Support of its MT1988 Cognitive Impairment Associated with Schizophrenia Program
Manchester, UK, 14 January 2025 Monument Therapeutics, a stratified medicine company developing novel treatments for areas of high unmet need in psychiatry and neurology, today announced that the Japan Patent Office (“JPO”) has granted Japanese patent 7570345, in support of its MT1988 program for cognitive impairment associated with schizophrenia (CIAS). The patent, which is expected […]
Monument Therapeutics Launches First Clinical Study of MT1988, a Novel Treatment for Cognitive Impairment Associated with Schizophrenia
Manchester, UK, 26 November 2024 Monument Therapeutics, a precision neuroscience company, today announced the first participant has been successfully dosed in its Phase I clinical study of MT1988, a novel treatment targeting cognitive impairment associated with schizophrenia (CIAS). MT1988 is a fixed-dose combination of two well-established small molecules that act on nicotinic receptors, designed to […]
Monument Therapeutics Announces Appointment of Dr Stephen Brannan, Dr Jeff Baker and Dr Mark Treherne to its Advisory Board to Guide Schizophrenia Program
Manchester, UK, 19 November 2024 Monument Therapeutics, a precision-neuroscience company focused on the development of innovative treatments for serious central nervous system disorders (CNS), is pleased to announce the addition of three distinguished experts to its Scientific Advisory Board (SAB). Leading the SAB as the new chairperson is Dr Mark Treherne, a research scientist with […]
